Our team of seasoned neuroscientists, neurologists, and molecular biologists possesses extensive experience in understanding the pathogenesis, progression, and potential therapeutic targets of Alzheimer’s disease. We are proficient in a variety of in vitro and in vivo Alzheimer’s disease assays, capable of evaluating the efficacy, safety, and pharmacokinetic properties of potential therapeutic compounds and cellular therapies.
Comprehensive Services Spanning the Alzheimer’s Disease Spectrum
We offer a comprehensive suite of preclinical Alzheimer’s disease services tailored to address the diverse challenges posed by this disease:
Neuroprotective and Disease-Modifying Compound Screening and Optimization: We utilize a range of in vitro and in vivo screening assays to identify promising neuroprotective and disease-modifying compounds, optimizing their potency, selectivity, and safety profile.
Pharmacokinetic and Pharmacodynamic (PK/PD) Studies: We determine the absorption, distribution, metabolism, and excretion (ADME) properties of potential therapeutic compounds, providing valuable insights into their pharmacokinetic profiles and pharmacodynamic effects in the central nervous system (CNS).
Regulatory Support and IND Preparation: We guide you through the intricate regulatory landscape, ensuring compliance with FDA guidelines and facilitating the preparation of Investigational New Drug (IND) applications.
